Related Experiment Video

Updated: Aug 26, 2026

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
07:49

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

Published on: July 21, 2023

Can natriuretic peptides be used for the diagnosis of diastolic heart failure?

U Dahlström1

  • 1Department of Cardiology, Linköping University hospital, Linköping, Sweden. Ulf.Dahlstom@lio.se

European Journal of Heart Failure
|February 28, 2004
PubMed

Insights

Diastolic dysfunction in heart failure is common but lacks a clear definition and management guidelines. While natriuretic peptides can aid diagnosis, normal levels do not rule out the condition, especially in mild cases.

Area of Science:

  • Cardiology
  • Heart Failure Research

Background:

  • Diastolic dysfunction, characterized by stiff hearts with increased wall thickness and small volumes, affects many heart failure patients.
  • Current definitions for diastolic heart failure are inconsistent, and large-scale management studies are scarce.

Purpose of the Study:

  • To explore the diagnostic utility of natriuretic peptides in identifying diastolic dysfunction.
  • To clarify the role of natriuretic peptides in managing heart failure patients with diastolic dysfunction.

Main Methods:

  • Review of existing literature and clinical guidelines on diastolic heart failure.
  • Analysis of the performance of natriuretic peptides (BNP or NT-proBNP) in detecting diastolic dysfunction across different patient subgroups.

Main Results:

  • Natriuretic peptides may help detect diastolic dysfunction in symptomatic patients with restrictive filling or pseudo-normal mitral flow patterns.
  • Normal natriuretic peptide levels can occur in patients with relaxation abnormalities and mild or no symptoms, indicating preserved left ventricular filling pressures.

Conclusions:

  • Natriuretic peptides are a useful, but not definitive, tool for diagnosing diastolic dysfunction in heart failure.
  • Low natriuretic peptide levels should not be used to exclude diastolic dysfunction, particularly in patients with subtle or asymptomatic disease.

More Related Videos

Pulsed Wave Doppler Assessment of Diastolic Dysfunction in the ZSF-1 Rat Model of Pulmonary Hypertension Due to Left Heart Disease08:57

Pulsed Wave Doppler Assessment of Diastolic Dysfunction in the ZSF-1 Rat Model of Pulmonary Hypertension Due to Left Heart Disease

Published on: May 22, 2026

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...